Sunshine Lake Pharma Co., Ltd. (HKG:6887)
Hong Kong · Delayed Price · Currency is HKD 36.96
+0.38 (1.04%)
Sep 11, 2026, 4:08 PM HKT
Sunshine Lake Pharma Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21,046 | 26,274 | 8,412 | 8,351 | 5,720 | 5,368 | |
Market Cap Growth | -32.29% | 212.32% | 0.74% | 46.00% | 6.56% | -30.92% |
Enterprise Value | 25,469 | 34,991 | 9,289 | 9,299 | 9,130 | 7,738 |
Last Close Price | 36.58 | 45.60 | 32.84 | 32.60 | 22.33 | 20.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 86.66 | - | 3.80 | 66.05 | - |
PS Ratio | 4.61 | 4.90 | 1.97 | 1.20 | 1.35 | 4.79 |
PB Ratio | 4.71 | 5.44 | 1.77 | 0.96 | 0.83 | 0.73 |
P/TBV Ratio | 7.51 | 8.25 | - | 1.41 | 1.71 | 1.19 |
P/FCF Ratio | - | 73.98 | - | 5.70 | 4.48 | - |
P/OCF Ratio | - | 20.44 | 15.79 | 4.53 | 2.98 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.58 | 6.53 | 2.17 | 1.34 | 2.16 | 6.90 |
EV/EBITDA Ratio | 45.01 | 28.61 | 11.94 | 2.66 | 11.68 | - |
EV/EBIT Ratio | - | 45.49 | 24.33 | 3.03 | 25.02 | - |
EV/FCF Ratio | - | 98.53 | - | 6.35 | 7.15 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.37 | 1.08 | 1.03 | 0.33 | 0.63 | 0.53 |
Debt / EBITDA Ratio | 10.82 | 4.06 | 5.95 | 0.82 | 5.46 | - |
Debt / FCF Ratio | - | 14.66 | - | 1.96 | 3.38 | - |
Net Debt / Equity Ratio | 0.99 | 0.73 | 0.70 | 0.12 | 0.43 | 0.34 |
Net Debt / EBITDA Ratio | 7.79 | 2.89 | 4.30 | 0.30 | 3.77 | -9.98 |
Net Debt / FCF Ratio | - | 9.96 | -5.59 | 0.70 | 2.31 | -2.02 |
Asset Turnover | 0.33 | 0.40 | 0.33 | 0.51 | 0.33 | 0.09 |
Inventory Turnover | 1.40 | 1.49 | 1.68 | 3.62 | 3.02 | 1.31 |
Quick Ratio | 0.50 | 0.56 | 0.70 | 0.87 | 0.46 | 1.36 |
Current Ratio | 0.76 | 0.77 | 1.03 | 1.40 | 1.01 | 1.66 |
Return on Equity (ROE) | -8.23% | 6.13% | 0.40% | 26.50% | 0.81% | -10.57% |
Return on Assets (ROA) | 0.38% | 3.61% | 1.82% | 14.16% | 1.80% | -2.85% |
Return on Invested Capital (ROIC) | 0.94% | 5.62% | 0.77% | 27.75% | 3.85% | -6.47% |
Return on Capital Employed (ROCE) | 1.20% | 11.60% | 5.00% | 33.20% | 4.60% | -4.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.56% | 1.15% | -2.62% | 26.29% | 1.51% | -13.44% |
FCF Yield | - | 1.35% | -7.10% | 17.54% | 22.33% | -23.30% |
Payout Ratio | - | 214.52% | - | - | - | - |
Buyback Yield / Dilution | -134.51% | -13.00% | -90.10% | - | - | 20.42% |
Total Shareholder Return | -118.77% | -13.00% | -90.10% | - | - | 20.42% |